Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 702

1.

Trends in oncologic hybrid imaging.

Wibmer AG, Hricak H, Ulaner GA, Weber W.

Eur J Hybrid Imaging. 2018;2(1):1. doi: 10.1186/s41824-017-0019-6. Epub 2018 Jan 19. Review.

PMID:
29782605
2.

[177Lu]-PSMA-617 Has Activity in Castration-Resistant Prostate Cancer.

[No authors listed]

Cancer Discov. 2018 May 18. doi: 10.1158/2159-8290.CD-RW2018-085. [Epub ahead of print]

PMID:
29776913
3.

The human somatostatin receptor type 2 as an imaging and suicide reporter gene for pluripotent stem cell-derived therapy of myocardial infarction.

Neyrinck K, Breuls N, Holvoet B, Oosterlinck W, Wolfs E, Vanbilloen H, Gheysens O, Duelen R, Gsell W, Lambrichts I, Himmelreich U, Verfaillie CM, Sampaolesi M, Deroose CM.

Theranostics. 2018 Apr 14;8(10):2799-2813. doi: 10.7150/thno.22980. eCollection 2018.

4.

BRCA2 Mutation as a Possible Cause of Poor Response to 177Lu-PSMA Therapy.

Ahmadzadehfar H, Gaertner F, Lossin PS, Schwarz B, Essler M.

Clin Nucl Med. 2018 May 14. doi: 10.1097/RLU.0000000000002141. [Epub ahead of print]

PMID:
29762244
5.

[177Lu]-PSMA-617 for targeted prostate cancer treatment: a magic bullet?

Paganelli G, De Giorgi U.

Lancet Oncol. 2018 May 7. pii: S1470-2045(18)30268-7. doi: 10.1016/S1470-2045(18)30268-7. [Epub ahead of print] No abstract available.

PMID:
29752181
6.

[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.

Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Ping Thang S, Akhurst T, Iravani A, Kong G, Ravi Kumar A, Murphy DG, Eu P, Jackson P, Scalzo M, Williams SG, Sandhu S.

Lancet Oncol. 2018 May 7. pii: S1470-2045(18)30198-0. doi: 10.1016/S1470-2045(18)30198-0. [Epub ahead of print]

PMID:
29752180
7.

Impressive Response to Tandem Treatment With [90Y]DOTATOC and [177Lu]DOTATOC in Grade 3 Pancreatic Neuroendocrine Carcinoma.

Lorenzoni A, Capozza A, Artale S, Maccauro M, Seregni EC.

Clin Nucl Med. 2018 May 7. doi: 10.1097/RLU.0000000000002116. [Epub ahead of print]

PMID:
29742602
8.

Evaluation of the Interaction of Amino Acid Infusion on 177Lu-Dotatate Pharmacokinetics in Patients with Gastroenteropancreatic Neuroendocrine Tumors.

Puszkiel A, Bauriaud-Mallet M, Bourgeois R, Dierickx L, Courbon F, Chatelut E.

Clin Pharmacokinet. 2018 May 8. doi: 10.1007/s40262-018-0674-1. [Epub ahead of print]

PMID:
29736841
9.

Multidose formulation of ready-to-use 177Lu-PSMA-617 in a centralized radiopharmacy set-up.

Chakraborty S, Vimalnath KV, Chakravarty R, Sarma HD, Dash A.

Appl Radiat Isot. 2018 Apr 26;139:91-97. doi: 10.1016/j.apradiso.2018.04.033. [Epub ahead of print]

PMID:
29734118
10.

Novel use of 177Lu-DOTA-RGD2 in treatment of 68Ga-DOTA-RGD2-avid lesions in papillary thyroid cancer with TENIS.

Parihar AS, Sood A, Kumar R, Bhusari P, Shukla J, Mittal BR.

Eur J Nucl Med Mol Imaging. 2018 May 1. doi: 10.1007/s00259-018-4036-x. [Epub ahead of print] No abstract available.

PMID:
29713764
11.

Prediction of Normal Organ Absorbed Doses for [177Lu]Lu-PSMA-617 Using [44Sc]Sc-PSMA-617 Pharmacokinetics in Patients With Metastatic Castration Resistant Prostate Carcinoma.

Khawar A, Eppard E, Sinnes JP, Roesch F, Ahmadzadehfar H, Kürpig S, Meisenheimer M, Gaertner FC, Essler M, Bundschuh RA.

Clin Nucl Med. 2018 Apr 23. doi: 10.1097/RLU.0000000000002102. [Epub ahead of print]

PMID:
29688951
12.

Lung Metastases of Intracranial Atypical Meningioma Diagnosed on Posttherapeutic Imaging After 177Lu-DOTATATE Therapy.

Backhaus P, Huss S, Kösek V, Weckesser M, Rahbar K.

Clin Nucl Med. 2018 Jun;43(6):e184-e185. doi: 10.1097/RLU.0000000000002077.

PMID:
29688946
13.

Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.

Umbricht CA, Benešová M, Schibli R, Müller C.

Mol Pharm. 2018 May 2. doi: 10.1021/acs.molpharmaceut.8b00152. [Epub ahead of print]

PMID:
29684274
14.

[Lutetium-177-PSMA radioligand therapy : Consensus within the framework of GKV-funded care between the university hospitals in Aachen, Bonn, Düsseldorf, Essen, and Cologne and the MDK Nordrhein].

Ahmadzadehfar H, Albers P, Bockisch A, Boegemann M, Böhme C, Burchert W, Dietlein M, Drzezga A, Fabry U, Feldmann G, Heidenreich A, Heinzel A, Herrmann K, Heyll A, Höhling C, Kreuzer C, Laufer D, Mengel R, Mottaghy FM, Müller HW, Müller SC, Ost E, Rahbar K, Reifenhäuser W, Schäfers M, Schlenkhoff C, Schmidt M, Schmidt-Wolf I, Wildenhain C, Zimmer B, Essler M.

Urologe A. 2018 Apr 18. doi: 10.1007/s00120-018-0642-2. [Epub ahead of print] Review. German.

PMID:
29671080
15.

Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy.

Mortensen AC, Spiegelberg D, Haylock AK, Lundqvist H, Nestor M.

Int J Oncol. 2018 Jun;52(6):1875-1885. doi: 10.3892/ijo.2018.4364. Epub 2018 Apr 11.

16.

Predictive factors of response and overall survival in patients with castration-resistant metastatic prostate cancer undergoing 177Lu-PSMA therapy.

Ahmadzadehfar H, Essler M.

J Nucl Med. 2018 Apr 13. pii: jnumed.118.209270. doi: 10.2967/jnumed.118.209270. [Epub ahead of print] No abstract available.

PMID:
29653975
17.

Safety, Pharmacokinetics and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analogue 177Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors.

Zhang J, Wang H, Jacobson Weiss O, Cheng Y, Niu G, Li F, Bai C, Zhu Z, Chen X.

J Nucl Med. 2018 Apr 13. pii: jnumed.118.209841. doi: 10.2967/jnumed.118.209841. [Epub ahead of print]

PMID:
29653971
18.

Preparation and dosimetry evaluation of a carrier- free 90Y labeled DOTMP as a Promising Agent for Bone marrow ablation.

Salek N, Vosoghi S, Arani SS, Samani AB, Mehrabi M, Maraghe MG.

Curr Radiopharm. 2018 Apr 12. doi: 10.2174/1874471011666180412165722. [Epub ahead of print]

PMID:
29651974
19.

External radiation exposure, excretion, and effective half-life in 177Lu-PSMA-targeted therapies.

Kurth J, Krause BJ, Schwarzenböck SM, Stegger L, Schäfers M, Rahbar K.

EJNMMI Res. 2018 Apr 12;8(1):32. doi: 10.1186/s13550-018-0386-4.

20.

Pharmacological upregulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells.

Kranzbühler B, Salemi S, Umbricht CA, Müller C, Burger IA, Sulser T, Eberli D.

Prostate. 2018 Apr 6. doi: 10.1002/pros.23522. [Epub ahead of print]

PMID:
29633296

Supplemental Content

Loading ...
Support Center